PERIPHERAL T-CELL LYMPHOMA (PTCL)
Clinical trials for PERIPHERAL T-CELL LYMPHOMA (PTCL) explained in plain language.
Never miss a new study
Get alerted when new PERIPHERAL T-CELL LYMPHOMA (PTCL) trials appear
Sign up with your email to follow new studies for PERIPHERAL T-CELL LYMPHOMA (PTCL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo targets Hard-to-Treat lymphomas
Disease control Recruiting nowThis study tests a new drug called AZD3470, alone or with pembrolizumab (Keytruda), in people with certain blood cancers like lymphoma. The goal is to check safety, side effects, and whether the drug shrinks tumors. About 161 adults and teens will take part.
Matched conditions: PERIPHERAL T-CELL LYMPHOMA (PTCL)
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Engineered immune cells take aim at stubborn lymphoma
Disease control Recruiting nowThis early-phase trial tests whether a personalized immune cell therapy called anti-EBV TCR-T cells is safe for people with relapsed or refractory EBV-positive lymphoma who have a specific genetic marker (HLA-A11:01). The treatment involves taking a patient's own T cells, enginee…
Matched conditions: PERIPHERAL T-CELL LYMPHOMA (PTCL)
Phase: EARLY_PHASE1 • Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC